immunoSEQ Blog

The Microbial Olympics

Untitled

This blog post is written in light of discomforting news about Ebola infections in Spain and case emergence in the US, as well as the breaking news of 628 respiratory enterovirus EV-D68 infections in 44 U.S. states, which in some patients caused severe respiratory illness and even polio-like symptoms. It appears to be an opportune… Read More→

Categorized in: Food for Thought |

Looking for inactive genes offers new angle for oncology treatments

Oncology has generally trended from generic treatments to more specific treatments.  For the most part, this has trended toward seeking the genetic anomalies within the cancer cells and targeting those mutations for specific treatment.  Generic treatments have dramatic and unavoidable side-affects, but specific treatments tend to be prone to drug resistance.  Researchers recently published in the August 28th issue… Read More→

Categorized in: Food for Thought |

New studies providing insights on the adaptive immune response

The adaptive immune response is believed to be shaped by signaling from the innate arm of the immune system. Three articles published on the September 25th issue of Science by the European BLUEPRINT initiative provide new insights into the latter. The first two studies use genome-wide epigenetic and transcription analyses to understand the phenomenon of… Read More→

Categorized in: Food for Thought |

Adaptive Customers Publish Latest Results in Cancer Immunology Research

Last week, a team of researchers from University of Pennsylvania and Adaptive Biotechnologies published results from a study in which they used the immunoSEQ assay to explore the immune activation of a patient with metastatic melanoma who responded to a treatment, underwent a single metastasectomy, and then achieved a complete remission ongoing for more than 9… Read More→

Categorized in: Announcements |

Adaptive Biotechnologies Attends Immunogenomics 2014

The HudsonAlpha Institute for Biotechnology and Science Magazine have collaborated to host a Conference on Immunogenomics this week in Huntsville, AL.  The Conference has brought together a cross-section of several hundred like-minded researchers and clinicians from academic and commercial organizations working at the intersection of genomics and immunology.   Plenary session topics have included genetic and epigenetic regulation… Read More→

Categorized in: Announcements |

Adaptive CEO Joins Distinguished Panel at Cancer Advance Conference in Boston

Screen Shot 2014-09-30 at 8.35.56 AM

Boston, MA: Adaptive Biotechnologies CEO Chad Robins joins distinguished panel at Cancer Advance Conference at Harvard Medical School. In the panel, “Next Generation – Omics Technologies: Innovation in Rx/Dx Strategies,” Mr. Robins will elucidate how Adaptive’s assays are being incorporated into clinical trials in blood cancers and solid tumors. He will also introduce the clinical… Read More→

Categorized in: Announcements |

Adaptive Announces the Formation of a Hematologic Malignancies Scientific Advisory Board

Highly distinguished advisory board to strengthen incorporation of Next Generation Sequencing (NGS) into clinical care for patients with blood cancers SEATTLE, September 29, 2014 – Adaptive Biotechnologies, a clinical stage diagnostics company that leverages Next Generation Sequencing to profile the adaptive immune system, announced today that it has established a Scientific Advisory Board to provide strategic and… Read More→

Categorized in: Announcements |

Sequence All The Genomes!!

All of the cool kids are sequencing people’s genomes these days: in the last year, more than 200,000 whole genomes were sequenced around the world. Most of those sequences were produced by machines from Illumina, Inc., and Illumina president Francis deSouza expects the number of sequenced human genomes to double every 12 months for the… Read More→

Categorized in: Food for Thought |